Last reviewed · How we verify
Nicotine lower dose
At a glance
| Generic name | Nicotine lower dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population (EARLY_PHASE1)
- Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect (NA)
- IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior (NA)
- Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs (NA)
- Effectiveness of Different THR Products in Adult Population (PHASE3)
- Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving (PHASE2)
- Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking (PHASE4)
- Photoirritation and Photoallergic Potential of a New Nicotine Patch (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine lower dose CI brief — competitive landscape report
- Nicotine lower dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI